ABIN952389

antibody from antibodies-online

Targeting: FRAT2

Provider product page for ABIN952389

Western blot

Immunocytochemistry

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [4]
Comments [0]
Validations
Western blot [1]
Immunocytochemistry [1]
Immunohistochemistry [1]

Submit

Product number: ABIN952389 - Provider product page
Provider: antibodies-online
Product name: anti-Frequently Rearranged in Advanced T-Cell Lymphomas 2 (FRAT2) (AA 210-233), (C-Term) antibody
Antibody type: Polyclonal
Description: Protein A column, followed by peptide affinity purification
Reactivity: Human
Host: Rabbit
Epitope: AA 210-233, C-Term
Vial size: 0.4 mL
Storage: Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
Handling: Avoid repeated freezing and thawing.

FRAT2 protein structure - ABIN952389 shown in red.

Submitted references Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization.

Abramowitz M, Muntner P, Coco M, Southern W, Lotwin I, Hostetter TH, Melamed ML
Clinical journal of the American Society of Nephrology : CJASN 2010 Jun;5(6):1064-71

Activation of glycogen synthase kinase-3 inhibits protein phosphatase-2A and the underlying mechanisms.

Liu GP, Zhang Y, Yao XQ, Zhang CE, Fang J, Wang Q, Wang JZ
Neurobiology of aging 2008 Sep;29(9):1348-58

FRAT-2 preferentially increases glycogen synthase kinase 3 beta-mediated phosphorylation of primed sites, which results in enhanced tau phosphorylation.

Stoothoff WH, Cho JH, McDonald RP, Johnson GV
The Journal of biological chemistry 2005 Jan 7;280(1):270-6

The DNA sequence and comparative analysis of human chromosome 10.

Deloukas P, Earthrowl ME, Grafham DV, Rubenfield M, French L, Steward CA, Sims SK, Jones MC, Searle S, Scott C, Howe K, Hunt SE, Andrews TD, Gilbert JG, Swarbreck D, Ashurst JL, Taylor A, Battles J, Bird CP, Ainscough R, Almeida JP, Ashwell RI, Ambrose KD, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Bates K, Beasley H, Bray-Allen S, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Cahill P, Camire D, Carter NP, Chapman JC, Clark SY, Clarke G, Clee CM, Clegg S, Corby N, Coulson A, Dhami P, Dutta I, Dunn M, Faulkner L, Frankish A, Frankland JA, Garner P, Garnett J, Gribble S, Griffiths C, Grocock R, Gustafson E, Hammond S, Harley JL, Hart E, Heath PD, Ho TP, Hopkins B, Horne J, Howden PJ, Huckle E, Hynds C, Johnson C, Johnson D, Kana A, Kay M, Kimberley AM, Kershaw JK, Kokkinaki M, Laird GK, Lawlor S, Lee HM, Leongamornlert DA, Laird G, Lloyd C, Lloyd DM, Loveland J, Lovell J, McLaren S, McLay KE, McMurray A, Mashreghi-Mohammadi M, Matthews L, Milne S, Nickerson T, Nguyen M, Overton-Larty E, Palmer SA, Pearce AV, Peck AI, Pelan S, Phillimore B, Porter K, Rice CM, Rogosin A, Ross MT, Sarafidou T, Sehra HK, Shownkeen R, Skuce CD, Smith M, Standring L, Sycamore N, Tester J, Thorpe A, Torcasso W, Tracey A, Tromans A, Tsolas J, Wall M, Walsh J, Wang H, Weinstock K, West AP, Willey DL, Whitehead SL, Wilming L, Wray PW, Young L, Chen Y, Lovering RC, Moschonas NK, Siebert R, Fechtel K, Bentley D, Durbin R, Hubbard T, Doucette-Stamm L, Beck S, Smith DR, Rogers J
Nature 2004 May 27;429(6990):375-81